SEARCH

SEARCH BY CITATION

References

  • 1
    Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 20892094.
  • 2
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatol 2004; 11: 97107.
  • 3
    Chen C-J, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 6573.
  • 4
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen C-J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678686.
  • 5
    Keeffe EB, Dieterich DT, Han SHB, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 13151341.
  • 6
    Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007; 45: 507539.
  • 7
    Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263283.
  • 8
    Cooksley WGE, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatol 2003; 10: 298305.
  • 9
    Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 26822695.
  • 10
    Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 14221427.
  • 11
    Chang T-T, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis. J Gastroenterol Hepatol 2004; 19: 2761282.
  • 12
    Lai CL, Gane E, Hsu CW, Thongsawat S, Wang Y, Chen Y, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine vs. lamivudine [Abstract]. HEPATOLOGY 2006; 44 ( Suppl. 1): 222A.
  • 13
    Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 25762588.
  • 14
    Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 24422455.
  • 15
    Marcellin P, Chang T-T, Lim SGL, Sievert W, Tong M, Arterburn S, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. HEPATOLOGY 2008; 48: 750758.
  • 16
    Heathcote EJ, Gane EJ, deMan RA, Chan S, Sievert W, Mauss S, et al. Two-year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis [Abstract]. HEPATOLOGY 2008; 48 ( Suppl.): 376A.
  • 17
    Snow-Lampart A, Chappell BJ, Curtis M, Zhu Y, Borroto-Esoda K. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300mg QD [Abstract]. HEPATOLOGY 2008; 48 ( Suppl.): 745A.
  • 18
    Chang TT, Gish RG, de Man RA, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 10011010.
  • 19
    Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 14371444.
  • 20
    Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. HEPATOLOGY 2006; 44: 16561665.
  • 21
    Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902911.
  • 22
    Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside naive patients is rare through 5 years of therapy. HEPATOLOGY 2009; 49: 15031514.
  • 23
    Colonno RJ, Rose R, Pokornowski K, Baldick, CT, Eggers, B, Yu D, et al. Four-year assessment of entecavir resistance in nucleoside naïve and lamivudine refractory patients [Abstract]. J Hepatol 2007; 46 ( Suppl. 1): S294.
  • 24
    Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 16101614.
  • 25
    Iloeje U, Yang H-I, Su J, Chen C-F, Jen C-L, You S-L, et al. HBV viral load less than 104 copies/mL is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B (CHB) patients: an update from the R. E.V.E.A.L.-HBV study [Abstract]. HEPATOLOGY 2007; 46 ( Suppl. 1): 640A.
  • 26
    Takehara T, Hayashi N, Takaguchi K, Yokosuka O, Fujioka S, Shindo M, et al. Efficacy and safety of 3 years treatment with entecavir (ETV) in Japanese nucleoside-naïve patients with chronic hepatitis B (CHB) [Abstract]. Hepatol Int 2008; 2: S311.